Sequential Acinetobacter lwoffii Bacteremia and Early Carbapenem-Resistant Acinetobacter baumannii Pneumonia in Diabetic Ketoacidosis: A Case Report
Abstract
Acinetobacter lwoffii (A. lwoffii) is traditionally considered a low-virulence commensal organism, yet it can cause invasive infections in immunocompromised hosts. The sequential appearance of A. lwoffii bacteremia with carbapenem-resistant Acinetobacter baumannii (A. baumannii) (CRAB) infection in the same patient is rarely reported and presents unique diagnostic and therapeutic challenges. We describe a case of a 51-year-old male with underlying diabetes mellitus and a background of chronic alcohol use who presented with septic shock secondary to bilateral pneumonia, complicated by underlying diabetic ketoacidosis (DKA). Admission blood cultures grew A. lwoffii bacteremia with pan-susceptibility except for colistin resistance. Deep endotracheal aspirate cultures later grew extensively drug‑resistant A. baumannii. The patient received sequential targeted antimicrobial therapy comprising meropenem for A. lwoffii bacteremia with the addition of colistin for CRAB pneumonia, alongside aggressive supportive care, resulting in complete recovery and discharge. This report highlights the pathogenic potential of A. lwoffii in diabetic patients with metabolic decompensation and emphasizes the importance of recognizing mixed Acinetobacter infections in critically ill patients. Timely microbiological diagnosis and appropriate antimicrobial therapy are essential for favorable outcomes.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.